SMAD3 and Hepatic fibrosis: Various active ingredient mechanisms in managing liver fibrosis include the NF‐κB signaling pathway (5 studies: [46–50]), the TGF‐β1/Smad3 signaling pathway (12 studies: [53–64]), MAPK, Wnt, and PI3K/Akt signaling pathways (4 studies [65–68]), Hedgehog signaling [51], the PPAR signaling pathway [52], the IFN‐γ/STAT1/Smad7 signaling pathways [69], the GSK‐3β pathway [70], the gut–liver axis [71], the PDGFRβ signaling pathway [72], and other mechanisms not specifying signaling pathways ([19, 73–75]).